In the analyses of selpercatinib‐ or pralsetinib‐resistant patients with RET fusions (NSCLC or medullary thyroid cancer), several secondary mutations have been reported (Figure 2B,C). The gene discussed is RET; the disease is medullary thyroid gland carcinoma.